Description
Nelarabine is an anticancer chemotherapeutic compound used to treat T-cell malignancies such as acute lymphoblastic leukemia (ALL). Nelarabine is the prodrug of 9-β-D-arabinofuranosylguanine (ara-G), and acts as a nucleoside analog of guanosine, inhibiting DNA synthesis.
References
Forcade E, Leguay T, Vey N, et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transplant. 2013 Jul;19(7):1124-6. PMID: 23648236.
Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. PMID: 22591387.
Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol. 2010 Dec 1;4:133-41. PMID: 21151585.
Reilly KM, Kisor DF. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28. PMID: 20616909.
Buie LW, Epstein SS, Lindley CM. Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007 Sep;29(9):1887-99. PMID: 18035189.